First Eagle Investment Management
CLDX icon

First Eagle Investment Management’s Celldex Therapeutics CLDX Stock Holding History

First Eagle Investment Management’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-29,667
Closed -$1.8M – 336
2016
Q3 		$1.8M Hold
29,667
– – ﹤0.01% 222
2016
Q2 		$1.95M Sell
29,667
-12,302
-29% -$781K 0.01% 225
2016
Q1 		$2.38M Buy
41,969
+3,333
+9% +$375K 0.01% 199
2015
Q4 		$9.09M Buy
38,636
+1,333
+4% +$291K 0.02% 163
2015
Q3 		$5.9M Hold
37,303
– – 0.01% 170
2015
Q2 		$14.1M Hold
37,303
– – 0.03% 155
2015
Q1 		$15.6M Hold
37,303
– – 0.04% 152
2014
Q4 		$10.2M Buy
37,303
+20,636
+124% +$5.13M 0.02% 164
2014
Q3 		$3.24M Buy
+16,667
New +$3.63M 0.01% 200
2014
Q1 		– Sell
-9,000
Closed -$3.27M – 391
2013
Q4 		$3.27M Sell
9,000
-27,667
-75% -$10.7M 0.01% 177
2013
Q3 		$19.5M Sell
36,667
-7,704
-17% -$2.64M 0.06% 137
2013
Q2 		$10.4M Buy
+44,371
New +$8.74M 0.03% 169

Other funds holding CLDX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KE
KLP Enterprises Branford, Connecticut $1.97M AUM
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

First Eagle Investment Management's CLDX Position: Q4 2016 in Review

First Eagle Investment Management sold out of Celldex Therapeutics (CLDX) in Q4 2016, closing a stake of 29,667 shares — an estimated $1.8M sold.

First Eagle Investment Management first reported a position in CLDX in Q2 2013 and held it in 12 quarters. The position peaked at $19.5M in Q3 2013. 140 funds tracked by Wall St. Rank hold CLDX as of Q4 2016.

  • First Eagle Investment Management reported no remaining Celldex Therapeutics position as of Q4 2016 after selling out during the quarter.
  • First Eagle Investment Management sold 29,667 Celldex Therapeutics shares in Q4 2016, an estimated $1.8M.
  • First Eagle Investment Management first reported a position in Celldex Therapeutics in Q2 2013 and held it in 12 quarters.
  • First Eagle Investment Management's Celldex Therapeutics position peaked at $19.5M in Q3 2013.
  • 140 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q4 2016.

Based on First Eagle Investment Management's 13F filing for Q4 2016, filed 6 Feb 2017.